Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Gossamer Bio (GOSS) reported a Q3 loss of $0.14 per share, which was better than the Zacks Consensus Estimate of a $0.18 loss. This is an improvement from the $0.21 loss per share reported a year ago.
November 08, 2024 | 12:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gossamer Bio reported a Q3 loss of $0.14 per share, beating the Zacks Consensus Estimate of a $0.18 loss. This marks an improvement from the previous year's $0.21 loss per share.
The better-than-expected earnings report is likely to have a positive short-term impact on Gossamer Bio's stock price. Beating the consensus estimate and showing improvement from the previous year are positive indicators for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100